Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting
– 82% ORR (27 of 33 pts) and 48% CR/CRh (16 of 33 pts) in SAVE trial studying revumenib in combination with venetoclax and decitabine/cedazuridine in R/R AML – – 64% ORR (62 of 97 pts) and 23% CR/CRh (22 of 97 pts) with high rates of MRD negativity and ability to pr
Media Advisory -Prime Minister’s itinerary for Sunday, December 8, 2024
OTTAWA, ON, Dec. 7, 2024 /CNW/ – National Capital Region, Canada No public events scheduled This document is also available at https://pm.gc.ca SOURCE Prime Minister’s Office
New Data from PROMMIS Study Highlights the Power of SKY92 in Identifying High-Risk Multiple Myeloma Patients
ROTTERDAM, the Netherlands and SAN DIEGO, Dec. 7, 2024 /PRNewswire/ — SkylineDx, an innovative diagnostics company specializing in the research and development of molecular diagnostics for oncology, inflammatory, and infectious diseases, announce that groundbreaking data on the Prognostic Valu
MosquitoMate receives first Vector Expedited Review Voucher (VERV) from the US Environmental Protection Agency
LEXINGTON, Ky., Dec. 7, 2024 /PRNewswire/ — The US Environmental Protection Agency (EPA) has just announced MosquitoMate as its first awardee in a new effort to fight the growing crisis of mosquito transmitted diseases. To help address the growing problem, in 2022 Congress mandated that the EP
Building Homes for Heroes Gifts 400th Home, Marking Historic Achievement in Veteran and First Responder Support
Building Homes for Heroes & Hillwood Properties partner to gift milestone home in Dallas, Texas NEW YORK, Dec. 7, 2024 /PRNewswire/ — Building Homes for Heroes today marked a transformative milestone with the gifting of its 400th home to U.S. Army Specialist Joshua Sager and his family in
Updated Results of Phase 3 ALLELE Study Presented at 66th American Society of Hematology Annual Meeting Confirm Efficacy, Safety and Durability of Novel Allogeneic Cell Therapy Tabelecleucel in Relapsed or Refractory Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
Tabelecleucel treated relapsed or refractory EBV+ PTLD patients achieved a 50.7% Objective Response Rate (ORR), 23.0-month Median Duration of Response (DOR), and Median Overall Survival (OS) of 18.4 months Safety findings consistent with prior studies with no reports of cytokine release syndro
Blueprint Medicines’ Continued Leadership in Redefining the Standard of Care in Systemic Mastocytosis Highlighted at 2024 ASH Annual Meeting
— ASH data reinforce survival benefits of front-line AYVAKIT® (avapritinib) use in patients with advanced SM — — Bone density analyses reported in patients with advanced SM underscore disease-modifying effects of AYVAKIT — CAMBRIDGE, Mass., Dec. 7, 2024 /PRNewswire/ —
Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting
73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN FRANCISCO, Dec. 7
Ethara: THE ART OF CURATING THE ABU DHABI GRAND PRIX HOSPITALITY EXPERIENCE
ABU DHABI, UAE, Dec. 7, 2024 /PRNewswire/ — The tens of thousands of visitors at this week’s Abu Dhabi Grand Prix will get to enjoy the biggest ever choice of restaurants, stalls, and beverage spots at Yas Marina Circuit to refresh and refuel over race weekend. Over 100 F&B spo
Phase 2 data from the ongoing HIBISCUS study shows promise that investigational etavopivat could reduce the incidence of vaso-occlusive crises in people with sickle cell disease
Data indicated a trend toward reduced incidence of vaso-occlusive crises over 52 weeks and increased hemoglobin response at 24 weeks compared with placebo Results to be confirmed in the phase 3 component of the HIBISCUS trial PLAINSBORO, N.J., Dec. 7, 2024 /PRNewswire/ — Novo Nordisk today ann
